YouMed

Versione italiana

last video

Metastatic Melanoma: 5-year survival rates may soon reach 60%

Prof. Claus Garbe
Head of the Division of Dermatooncology
Eberhard Karls University, Tuebingen (Germany)

At the beginning of this decade, the average survival of patients with metastatic melanoma was 7 months and the 5-year rate was 3%. Thanks to the introduction of new drugs such as Vemurafenib and Ipilimumab, the survival rate rose to 20% and now, with PD-1 and CTLA-4 antibodies and combined targeted treatments based on BRAF and MEK inhibitors, survival is 40-50% . Prof. Garbe explains why a 5-year rate of 60-70% could be achieved in the near future.

Macular degeneration: retina rejuvenation with the 2RT laser

Prof. John Marshall
Emeritus Professor of Ophthalmology
Moorfields Eye Hospital, University of London

At the Euretina congress, Prof. John Marshall, who developed the clinical use of 2RT laser in macular degeneration, presented the results of a clinical trial whose purpose is to determine whether 2RT nanosecond laser therapy slows the progression to advanced age-related macular degeneration. According to the researcher, the study shows that the treatment can slow the progression of the disease up to 4 times.

What is needed to win the battle against cancer

Prof. Franco Cavalli
Scientific Director, Oncology Institute of Southern Switzerland, S. Giovanni Hospital Bellinzona, CH

Can the battle against cancer be lost? From a diagnostic and therapeutic point of view, the progress made in recent years has been irrefutable. The outlook is less rosy when considering the global mortality rate, in the light of the distribution of the most effective and advanced resources used to fight the disease. 75% of anticancer drugs are consumed in Europe, North America and Japan, while as many as 30 other countries in the world do not even have a single radiotherapy device.

highlights

focus events

THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY

An educational meeting dedicated to sarcomas and GIST to improve diagnostic and therapeutic quality

32nd CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY

European and worldwide cardiologists address cutting edge scientific and clinical topics

15TH INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

The world's leading forum on both basic and clinical research for the sixth most common cancer pathology

WORLD DERMATOLOGY IN MILAN

The Congress focused on results related to numerous new therapies, both for inflammatory diseases and cutaneous tumors

FOCUS ON CORONARY PHYSIOLOGY AND CUTTING-EDGE TOPICS

Intracoronary pressure measurement and functional assessment of coronary stenosis severity in 2019

SPOTLIGHT ON INTERVENTIONAL CARDIOLOGY

11,200 participants from over 120 countries. 400 sessions and numerous live demonstrations

Hot topic from the 32nd ESC Congress in Paris

Clinical consequences of gender differences in the management of cardiovascular diseases. 8 videos. Click here

...

Focus on coronary physiology

Corso teorico pratico d'impanto multidisciplinare sulle innovazioni tecnologiche nel settore cardiovascolare. 27 video. Clicca qui

...

PCR 2019: MeRes-1 Study presented by Dr. Praveen Chandra

Study on thin-strut sirolimus-eluting bioresorbable vascular scaffold. Grant/Research support: Meril Life Sciences. Click here

...

International Multidisciplinary Seminar

Important advances in understanding headaches and pharmacological treatments. 12 videos. Click here

...

Pulmonary Arterial Hypertension

A new association aims to intensify scientific research and make the recent multiple advances in the diagnosis and treatment of the disease available worldwide. Click here

...

Vancouver 2018 - International Menopause Society congress

A 4-day event on Health Care, Women's Health, Metabolism, Hormones, Menopause and Climacteric issues. 12 videos.Click here

...

2018 European Congress

Symposium, sponsored by Alfasigma, addressing the causes of decreasing fertility both in the male and in the woman. 12 videos. Click here

Cookies helps us to provide our services. Using these services , you agree to use of cookies on our part. OK